This morning, the biopharmaceutical company Valneva unveiled encouraging final data for its Lyme disease vaccine candidate, VLA15, from a Phase 2 study. The clinical trial confirms a robust immune response and a favorable safety profile across all age groups studied, including children, six months after the third annual injection. These results validate the dosing regimen of three injections followed by annual boosters before each transmission season.
The stock rose by 7.44% at the opening, moving from €3.79 yesterday to €4.07 this Wednesday morning. This increase is part of a positive trend as over the past seven days, the stock has gained 7.73%, almost entirely concentrated in this session. In the longer term, the annual performance has reached 102.1%, significantly outperforming the CAC 40's twelve-month progression, which is limited to 10.9%. The group recently confirmed its outlook despite the suspension of one of its vaccines in the United States. However, trading remains moderate with only 0.35% of the capital mobilized this morning, indicating some restraint despite the announcement. The overall market is showing a timid progression, with the Paris index gaining only 0.28% in parallel, which relatively amplifies Valneva's upward movement.
Short-Term Selling Pressure Despite Positive News
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The stock is slightly below its 50-day moving average, positioned at €4.21, indicating a slight selling pressure in the short term despite the favorable announcement. Conversely, Valneva maintains a well-established position above its 200-day moving average, set at €3.43, confirming the solidity of the long-term upward trend. Between these two technical levels, the stock has a comfortable margin of progression before encountering significant resistance.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
